| Literature DB >> 27818699 |
Jae-Woo Shim1, Jae-Young Jung1, Sung-Soo Kim2.
Abstract
Purpose. This study aims to verify the effects of electroacupuncture treatment on osteoarthritis of the knee. Methods. MEDLINE/PubMed, EMBASE, CENTRAL, AMED, CNKI, and five Korean databases were searched by predefined search strategies to screen eligible randomized controlled studies meeting established criteria. Any risk of bias in the included studies was assessed with the Cochrane Collaboration's tool. Meta-analysis was conducted using RevMan version 5.3 software. Results. Thirty-one randomized controlled studies of 3,187 participants were included in this systematic review. Meta-analysis was conducted with eight studies including a total of 1,220 participants. The electroacupuncture treatment group showed more significant improvement in pain due to knee osteoarthritis than the control group (SMD -1.86, 95% CI -2.33 to -1.39, I2 75%) and in total WOMAC score than the control group (SMD -1.34, CI 95% -1.85 to -0.83, I2 73%). Compared to the control group, the electroacupuncture treatment group showed more significant improvement on the quality of life scale. Conclusion. Electroacupuncture treatment can relieve the pain of osteoarthritis of the knees and improve comprehensive aspects of knee osteoarthritis and the quality of life of patients with knee osteoarthritis.Entities:
Year: 2016 PMID: 27818699 PMCID: PMC5081971 DOI: 10.1155/2016/3485875
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow diagram of the study selection process.
Characteristics of included studies.
| First author (year) | Sample size (M/F) | Diagnostic criteria (radiologic evidence) | Mean age | Experimental group | Control group | Outcomes | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Intervention type | Total session | Duration/evaluation time points after baseline |
| Intervention type |
| |||||
| Li [ | 76 (36/40) | Chinese Rheumatology Association criteria | n.r. | EA | 15 | 3 weeks/3 weeks | 38 | Medication (celecoxib 100 mg bid) | 38 | HSS knee score |
|
| ||||||||||
| Wu [ | 100 (36/64) | ACR | 61 | EA | 14 | 4 weeks/2 weeks, 4 weeks | 50 | Medication (topical diclofenac diethylamine emulgel 20 g qd) | 50 | Lequesne index |
|
| ||||||||||
| Ying [ | 171 (76/95) | n.r. | 58 | EA | 21 | 8 weeks/8 weeks | 57 | MA (same points) | 57 | Efficacy rate |
|
| ||||||||||
| Huang [ | 168 (85/83) | ACR | 59.6 | EA | 36 | 6 weeks/3 weeks, 6 weeks, 6 months | 58 | Medication (glucosamine hydrochloride 75 mg bid)/EA (same points) | 53 | Lequesne index |
|
| ||||||||||
| Li [ | 100 (36/64) | ACR (K-L grade) | 61 | EA | 20 | 23 days/23 days, 6 months | 50 | MA (tug-of-war needling, similar points) physiotherapy (thermotherapy) | 50 | WOMAC |
|
| ||||||||||
| Plaster [ | 60 (11/49) | ACR | 63.2 | EA | 1 | 1 day/immediately after treatment | 30 | MA (same points) | 30 | NRS |
|
| ||||||||||
| Ruan [ | 72 (39/33) | ACR | 55 | EA | 21 | 25 days/25 days | 38 | Medication (glucosamine hydrochloride 750 mg bid) | 34 | Lequesne index |
|
| ||||||||||
| Ruan [ | 88 (42/46) | ACR | 53.6 | EA | 24 | 8 weeks/8 weeks | 45 | Medication (glucosamine hydrochloride 240 mg tid) | 43 | Efficacy rate |
|
| ||||||||||
| Fu [ | 208 (103/105) | ACR | 58.3 | EA | 24 | 4 weeks/4 weeks, 9 weeks | 70 | Medication (ibuprofen 0.3 g bid)/MA (same points) | 70 | WOMAC |
|
| ||||||||||
| Zhao [ | 93 (n.r.) | ACR | n.r. | EA | 12 | 4 weeks/1 week, 2 weeks, 4 weeks | 33 | Medication (celecoxib 20 mg tid) | 19 | VAS |
|
| ||||||||||
| Zhu [ | 55 (22/33) | ACR (K-L grade) | 68.7 | EA | 14 | 4 weeks/4 weeks, 12 weeks | 28 | Medication (diclofenac sodium 75 mg qd) | 27 | WOMAC |
|
| ||||||||||
| Che [ | 63 (25/38) | ACR | 52 | EA | 10 | 20 days/20 days | 32 | Medication (diclofenac sodium 75 mg qd) | 31 | Efficacy rate |
|
| ||||||||||
| Li [ | 100 (37/63) | Chinese Orthopedic Association Criteria | 53.8 | EA | 20 | 4 weeks/4 weeks | 50 | MA (similar points) | 50 | Efficacy rate |
|
| ||||||||||
| Mavrommatis [ | 120 (29/91) | ACR (K-L grade) | 61.8 | EA | 16 | 8 weeks/4 weeks, 8 weeks, 12 weeks | 40 | Sham EA† medication (etoricoxib 60 mg qd)/medication (etoricoxib 60 mg qd) | 40 | WOMAC |
|
| ||||||||||
| Teng [ | 86 (32/54) | ACR | 61 | EA | 24 | 8 weeks/8 weeks | 30 | MA (same points) | 26 | Efficacy rate |
|
| ||||||||||
| Ji [ | 70 (31/39) | ACR | 56 | EA | 24 | 8 weeks/8 weeks | 35 | Medication (meloxicam 7.5 mg qd) | 35 | Lequesne index |
|
| ||||||||||
| Meng [ | 69 (16/53) | n.r. | n.r. | EA | 9 | 3 weeks/8 weeks, 20 weeks | 28 | Medication (acetaminophen 500 mg qid/free) | 18 | Knee score and functional score |
|
| ||||||||||
| Lu [ | 20 (n.r.) | n.r. (K-L grade) | 63.8 | EA | 1 | 1 day/immediately after treatment | 10 | Sham EA§ | 10 | VAS |
|
| ||||||||||
| Wu [ | 80 (34/46) | ACR | 48.6 | EA | 20 | 23 days/23 days | 40 | Medication (fenbid 30 mg bid) | 40 | Efficacy rate |
|
| ||||||||||
| Ahsin [ | 84 (n.r.) | ACR | n.r. | EA | 10 | 10 days/10 days | 26 | Sham EA§ | 58 | VAS |
|
| ||||||||||
| Hou [ | 50 (24/26) | ACR | 62.5 | EA | 24 | 30 days/30 days | 25 | MA (same points) | 25 | Efficacy rate |
|
| ||||||||||
| Jubb [ | 68 (13/55) | n.r. | 65.1 | EA | 10 | 5 weeks/5 weeks, 9 weeks | 34 | Sham EA† | 34 | WOMAC |
|
| ||||||||||
| Wu [ | 40 (15/25) | ACR | 61.8 | EA | 12 | 4 weeks/4 weeks | 20 | Medication (diclofenac sodium 25 mg tid) | 20 | Lysholm scale |
|
| ||||||||||
| Qiu [ | 60 (9/51) | ACR | 55.7 | EA | 8 | 4 weeks/2 weeks, 4 weeks | 30 | Medication (Voltaren 75 mg qd) | 30 | WOMAC |
|
| ||||||||||
| Berman [ | 570 (205/365) | n.r. (K-L grade) | 65.5 | EA | 23 | 26 weeks/4 weeks, 8 weeks, 14 weeks, 26 weeks | 190 | Sham EA†/education | 191 | WOMAC |
|
| ||||||||||
| Tukmachi [ | 29 (5/24) | n.r. (K-L grade) | 62 | EA | 10 | 5 weeks/5 weeks, 9 weeks | 10 | Medication (current medication, n.r.)/EA (same points) | 10 | WOMAC |
|
| ||||||||||
| Vas [ | 97 (16/81) | ACR | 67.1 | EA | 12 | 12 weeks/12 weeks | 48 | sham EA† medication (diclofenac 50 mg tid/free) | 49 | WOMAC |
|
| ||||||||||
| Ng [ | 24 (1/23) | n.r. | 85 | EA | 8 | 2 weeks/2 weeks, 4 weeks | 8 | General education | 8 | NRS |
|
| ||||||||||
| Sangdee [ | 193 (43/150) | ACR | 62.9 | EA | 12 | 4 weeks/4 weeks | 49 | Sham ES‡ medication (diclofenac 25 mg tid/free)/EA with placebo medication | 49 | WOMAC |
|
| ||||||||||
| Berman [ | 73 (28/45) | ACR (K-L grade) | 65 | EA | 16 | 8 weeks/4 weeks, 8 weeks, 12 weeks | 37 | Medication (n.r.) | 36 | WOMACLequesne index |
|
| ||||||||||
| Yurtkuran [ | 100 (9/91) | n.r. | 58.1 | EA | 10 | 2 weeks/2 weeks | 25 | Sham ES‡ | 25 | PPI |
M/F: number of males/number of females, n: number, ACR: American College of Rheumatology criteria, K-L grade: Kellgren-Lawrence grade, n.r.: not reported, EA: electroacupuncture, MA: manual acupuncture, ES: electrical stimulation, qd: once a day, bid: twice a day, tid: three times a day, qid: four times a day, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index, VAS: visual analogue scale, NRS: numeric rating scale, PQLC: profile of quality of life in the chronically ill, PPI: present pain intensity, PPT: pressure pain threshold, TUG test: Timed Up-and-Go test, SF-36v2: Short-Form 36 version 2, SF-36: Short-Form 36-item Health Survey, HSS: Hospital for Special Surgery, IEMG and MF values: integrated electromyogram and median frequencies values measured by surface electromyography, ISOA: index of severity of osteoarthritis, and IDS: index of disease severity.
Multiple-arm study.
†Sham electroacupuncture using nonpenetrating acupuncture with sham electrical stimulation at the same points.
‡Sham electrical stimulation without acupuncture using patch electrodes at the same points.
§Sham electroacupuncture using penetrating acupuncture with sham electrical stimulation at nonacupoints.
Summary of information related to electroacupuncture treatments.
| First author (year) | Acupuncture rationale | Details of needling | Practitioner background | ||||
|---|---|---|---|---|---|---|---|
| Acupuncture points | ES frequency, Duration | De-qi | Depth of insertion | Needle type (diameter/length) | |||
| Li [ | TCM | EX-LE5, SP10, ST36, ST34, GB34, SP9, Ashi point | 20 Hz, 30 min | Elicited | n.r. | n.r./50.0 mm | n.r. |
|
| |||||||
| Wu [ | TCM | EX-LE5 | 40 Hz, 45~60 min | n.r. | 33.3 mm | n.r./50.0 mm | n.r. |
|
| |||||||
| Ying [ | TCM | ST35, EX-LE4, EX-LE2, SP10, ST36, GB34, SP9, BL40 | n.r., 30 min | Elicited | 25.4~38.1 mm | 0.30 mm/40 mm | n.r. |
|
| |||||||
| Huang [ | TCM | Ashi point, ST35, EX-LE4, SP10, EX-LE2, SP6, SP9, ST36, LR3 | 15 Hz, 30 min | Elicited | 15~20 mm | 0.35 mm/25 mm | n.r. |
|
| |||||||
| Li [ | TCM | ST35, EX-LE4, GB34, SP9, GB33, ST34, SP10, Ashi point | 2 Hz, 30 min | Elicited | 25~40 mm | 0.35 mm/40 or 50 mm | n.r. |
|
| |||||||
| Plaster [ | TCM according to previous study [ | LI4, LR3, ST36, ST35, EX-LE5, SP10 | 3 Hz and 100 Hz (alternate), 30 min | n.r. | 5 mm | 0.25 mm/30 mm | n.r. |
|
| |||||||
| Ruan [ | TCM | EX-LE4, SP9, LR8, SP10, ST35, ST36, GB33, ST34, EX-LE2, ST32, Ashi point | n.r., 30 min | Elicited | 33.3~5.0 mm | 0.30 mm/50 mm | n.r. |
|
| |||||||
| Ruan [ | TCM | ST34, SP10, GB34, ST36, SP9, GB39, Ashi point | n.r., 30 min | Elicited | n.r. | n.r./50.0 mm | n.r. |
|
| |||||||
| Fu [ | TCM | EX-LE5, SP9, GB34, BL40, EX-LE2 | n.r., 30 min | Elicited | n.r. | 0.35 mm/50~60 mm | n.r. |
|
| |||||||
| Zhao [ | TCM | CV8, EX-LE5, SP10, ST34 | n.r., 30 min | Elicited | n.r. | 0.25 mm/40~70 mm | n.r. |
|
| |||||||
| Zhu [ | TCM | Xian, GB34, SP9, ST36, Ashi point | 2 Hz and 100 Hz (alternate), 20 min | Elicited | n.r. | 0.25 mm/40 mm | n.r. |
|
| |||||||
| Che [ | TCM, western medical | EX-LE4, ST35 | 2 Hz, 45 min | Elicited | 60 mm | 0.45 mm/75 mm | n.r. |
|
| |||||||
| Li [ | TCM | EX-LE5, Ashi point, ST34, SP10, GB34, SP9, ST36, GB39 | n.r., 30 min | Elicited | 33.3 mm | 0.25 mm/40 mm | n.r. |
|
| |||||||
| Mavrommatis [ | TCM | ST36, SP9, SP10, GB34, Ex-LE 2, Ex-LE5, LI4, KI3, ST40, SP6 | 2 Hz~6 Hz, 20 min | Elicited | n.r. | 0.25 mm/30 mm | Doctor specializing in acupuncture |
|
| |||||||
| Teng [ | TMC | ST35, EX-LE4, EX-LE2, SP10, ST36, GB34 | n.r., 30 min | Elicited | 25.4~38.1 mm | 0.30 mm/40 mm | n.r. |
|
| |||||||
| Ji [ | TMC | ST35, EX-LE4, GB33, BL40, ST36, GB34, GB39 | 40 Hz~60 Hz, 30 min | Elicited | n.r. | 0.30 mm/40 mm | n.r. |
|
| |||||||
| Meng [ | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. |
|
| |||||||
| Lu [ | TCM | GB34, SP9, SP10, SP34, ST36 | 2 Hz, 30 min | Elicited | 10~15 mm | n.r. | Experienced acupuncturist |
|
| |||||||
| Wu [ | TCM, western medical | EX-LE5, SP10, ST34 | n.r., 30 min | Elicited | 26.7~40.0 mm | 0.35 mm/50 mm | n.r. |
|
| |||||||
| Ahsin [ | TCM | ST34, ST35, ST36, LR8, SP10, ST44 | 3 Hz, 20~25 min | Elicited | 10~30 mm | n.r./30 mm | Qualified acupuncturist |
|
| |||||||
| Hou [ | TCM | ST35, EX-LE2, ST34, GB34, SP9 | 3 Hz, 30 min | Elicited | n.r. | 0.30 mm/50 mm | n.r. |
|
| |||||||
| Jubb [ | TCM | LI4, SP10, EX-LE5, SP9, GB34, ST36, LR3, BL40, BL57 | 6 Hz, 20 min | Elicited | 10~15 mm | 0.25 mm/30 mm | Acupuncturist |
|
| |||||||
| Wu [ | TCM | EX-LE5, EX-LE2, SP10, SP11, ST34, ST36, SP9 | n.r., 20 min | Elicited | n.r. | n.r./n.r. | n.r. |
|
| |||||||
| Qiu [ | TCM, western medical | EX-LE5 | 2 Hz and 100 Hz (alternate), 30 min | Elicited | 5.1~6.4 mm | 0.45 mm/75 mm | n.r. |
|
| |||||||
| Berman [ | TCM | GB34, SP9, ST36, ST35, EX-LE5, UB60, GB39, SP6, KI3 | 8 Hz, 20 min | Elicited | 7.6~25.4 mm | 0.25 mm/38.1 or 25.4 mm | State-licensed acupuncturists who have at least 2 years of clinical experience |
|
| |||||||
| Tukmachi [ | TCM | LI4, SP10, EX-LE5, SP9, GB34, ST36, LR3, BL40, BL57 | 6 Hz, 20 min | Elicited | 10~15 mm | 0.25 mm/30 mm | Acupuncturist |
|
| |||||||
| Vas [ | TCM | GB34, SP9, Xian, ST36, LI4 | 2 Hz and 15 Hz (alternate), 20 min | Elicited | n.r. | 0.25 mm/45 mm | Doctor specializing in acupuncture† |
|
| |||||||
| Ng [ | TCM according to previous study [ | ST35, EX-LE4 | 2 Hz, 20 min | Elicited | 10~15 mm | 0.25 mm/40 mm | n.r. |
|
| |||||||
| Sangdee [ | TCM | ST35, EX-LE4, LR8, Trigger point (at the level of the joint line, midpoint between EX-LE4 and LR8) | 2 Hz, 20 min | Not intended | Superficially (under 12.7 mm) | n.r. | Acupuncturist who received acupuncture training in the People's Republic of China |
|
| |||||||
| Berman [ | TCM | GB34, SP9, ST36, ST35, EX-LE5, UB60, GB39, SP6, KI3 | 2.5 Hz~4 Hz, 20 min | Elicited | 10.2–15.2 mm | 0.22 mm/25.4 mm | n.r. |
|
| |||||||
| Yurtkuran [ | TCM | SP9, GB34, ST34, ST35 | 4 Hz, 20 min | n.r. | 12.7–25.4 mm | 0.25 mm/40 mm | n.r. |
TCM: traditional Chinese medicine, EA: electroacupuncture, ES: electrical stimulation, Hz: hertz, min: minutes, and n.r.: not reported.
Accredited by the International Council of Medical Acupuncture and Related Techniques (ICMART) and the Medical Acupuncture Society of Northern Greece.
†Accredited by Beijing University of Medical Sciences (China) and by the Scientific Society of Medical Acupuncture.
Figure 2Assessment of risk of bias.
Figure 5Effects of EA treatment versus sham EA on pain intensity. EA: electroacupuncture.
Figure 3Effects of EA treatment versus control interventions on pain intensity. EA: electroacupuncture.
Figure 4Effects of EA treatment plus drug therapy versus drug therapy alone on pain intensity. EA: electroacupuncture.
Figure 6Effects of EA treatment versus sham EA on pain intensity (meta-analysis using change scores from baseline). EA: electroacupuncture.
Figure 7Effects of EA treatment versus control group interventions on WOMAC total scores. EA: electroacupuncture; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 8Effects of EA treatment versus control on the SF-36 physical scale. EA: electroacupuncture; SF-36: 36-item Short-Form Health Survey.
Figure 9Effects of EA treatment versus control on mental state-related QOL. EA: electroacupuncture; QOL: quality of life.